Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436
that can be given in combination with topotecan chemotherapy in patients with advanced solid
tumours